Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness?
Depression results from changes in the central nervous system (CNS) that may result from immunological abnormalities. The immune system affects the CNS through cytokines, which regulate brain activities and emotions. Cytokines affect two biological systems that are most associated with the pathophysiology of depression: The hypothalamic-pituitary-adrenal axis and the catecholamine/sympathetic nervous system. Neuroinflammation and cytokines affect the brain signal patterns involved in the psychopathology of depression and the mechanisms of antidepressants, and they are associated with neurogenesis and neural plasticity. These observations suggest that neuroinflammation and cytokines might cause and/or maintain depression, and that they might be useful in the diagnosis and prognosis of depression. This psychoneuroimmunologic perspective might compensate for some of the limitations of the monoamine theory by suggesting that depression is a result of a failure to adapt to stress and that inflammatory responses and cytokines are involved in this process. In this review, the interactions of cytokines with the CNS, neuroendocrine system, neurotransmitters, neurodegeneration/neurogenesis, and antidepressants are discussed. The roles of cytokines in the etiology and psychopathology of depression are examined. The use of cytokine inhibitors or anti-inflammatory drugs in depression treatment is explored. Finally, the significance and limitations of the cytokine hypothesis are discussed.
Sang Won Jeon, Yong Ku Kim, Department of Psychiatry, College of Medicine, Korea University, Ansan Hospital, Seoul 02841, South Korea.
Sang Won
SW
Jeon
Sang Won Jeon, Yong Ku Kim, Department of Psychiatry, College of Medicine, Korea University, Ansan Hospital, Seoul 02841, South Korea.
Yong Ku
YK
Kim
Antidepressant; Cytokine; Depression; Neuroendocrine; Neurogenesis; Neuroinflammation; Neurotransmitter; Psychoneuroimmunology
Gen Hosp Psychiatry. 2003 Jan-Feb;25(1):34-8
12583926
J Affect Disord. 2007 Feb;98(1-2):143-51
16952400
Biol Psychiatry. 1995 Nov 1;38(9):611-21
8573663
Biol Psychiatry. 2009 Feb 15;65(4):296-303
18801471
Brain Behav Immun. 2010 Feb;24(2):173; author reply 174-5
19932747
Neurotox Res. 2006 Oct;10(2):149-60
17062376
J Neural Transm (Vienna). 1997;104(10):981-91
9503251
Prog Neuropsychopharmacol Biol Psychiatry. 1995 Jan;19(1):11-38
7708925
Neuro Endocrinol Lett. 2008 Jun;29(3):287-91
18580840
Trends Neurosci. 2008 Sep;31(9):464-8
18675469
Brain Behav Immun. 2002 Oct;16(5):525-32
12401466
Curr Immunol Rev. 2010 Aug;6(3):205-212
21170282
Neuropsychopharmacology. 2002 May;26(5):643-52
11927189
J Affect Disord. 2005 Oct;88(2):167-73
16126278
Biol Psychiatry. 2011 Apr 15;69(8):804-7
21377656
Neurosci Lett. 1996 Sep 13;215(3):201-4
8899748
Pharmacol Rep. 2013;65(6):1655-62
24553014
Am J Psychiatry. 2000 May;157(5):683-94
10784457
Mol Psychiatry. 2012 Dec;17(12):1161-3; author reply 1163-7
22824812
Psychol Rev. 1998 Jan;105(1):83-107
9450372
Mol Psychiatry. 2009 Dec;14(12):1095-104
18458677
Am J Psychiatry. 2001 Apr;158(4):575-81
11282691
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1355-61
18316149
Brain Res Bull. 2001 Mar 1;54(4):329-38
11306183
Neurosci Lett. 2011 Jul 20;499(2):74-9
21640159
J Affect Disord. 2001 Mar;63(1-3):171-8
11246093
Ann Med. 2003;35(1):2-11
12693607
Neuroscience. 2009 Feb 6;158(3):1021-9
18662748
Mol Psychiatry. 1996 Sep;1(4):336-42
9118360
Neuropsychopharmacology. 2004 Apr;29(4):777-84
14702025
Neuropsychopharmacology. 2014 Jan;39(1):242-3
24317319
Immunol Today. 1993 Apr;14(4):171-6
8499077
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9262-7
21518864
Nature. 2002 Dec 19-26;420(6917):853-9
12490958
Mol Pharmacol. 1997 Oct;52(4):571-81
9380019
J Neuroinflammation. 2009 Dec 10;6:36
20003262
Brain Res. 1994 Apr 18;643(1-2):40-9
7518332
Hum Psychopharmacol. 2010 Apr;25(3):201-15
20373471
J Clin Invest. 1988 Sep;82(3):839-46
2901433
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):201-17
15694227
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10440-3
1279679
CNS Spectr. 2008 Jun;13(6):501-10
18567974
Z Rheumatol. 2000;59 Suppl 2:II/26-30
11155800
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):751-6
18178625
Int J Neuropsychopharmacol. 2009 May;12(4):561-78
19224657
Nat Rev Neurosci. 2008 Jan;9(1):46-56
18073775
Adv Exp Med Biol. 1999;461:153-78
10442173
Endocrinology. 1999 Sep;140(9):4359-66
10465310
J Affect Disord. 1998 Jun;49(3):211-9
9629951
Biol Psychiatry. 2010 Mar 1;67(5):446-57
20015486
Viral Immunol. 2005;18(1):41-78
15802953
Hum Psychopharmacol. 2008 Mar;23(2):87-94
18172906
Int Immunopharmacol. 2006 Aug;6(8):1298-304
16782542
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:304-13
24184687
Eur J Pharmacol. 1997 Mar 26;323(1):21-6
9105872
Harv Rev Psychiatry. 2010 Sep-Oct;18(5):293-303
20825266
Stress. 2008 May;11(3):198-209
18465467
Neuroimmunomodulation. 1995 May-Jun;2(3):141-8
8646563
Neuroimmunomodulation. 2006;13(5-6):268-76
17709948
Biol Psychiatry. 1994 Jan 1;35(1):42-7
8167203
Brain Behav Immun. 2002 Oct;16(5):610-7
12401476
Transl Psychiatry. 2012 Feb 21;2:e79
22832816
Trans Assoc Am Physicians. 1991;104:238-47
1668987
Brain Res. 1995 Oct 16;695(2):279-82
8556346
J Alzheimers Dis. 2011;26(4):699-708
21709373
Psychol Med. 2012 Oct;42(10):2027-35
22391106
Science. 2003 Dec 5;302(5651):1760-5
14615545
Neuropsychopharmacology. 2011 Nov;36(12):2452-9
21796103
Biochem Biophys Res Commun. 1995 Nov 13;216(2):560-7
7488148
J Leukoc Biol. 1996 Nov;60(5):563-72
8929546
Pharmacol Ther. 1996;69(2):85-95
8984509
Adv Exp Med Biol. 1999;461:107-16
10442170
Ann N Y Acad Sci. 2000;917:608-17
11268389
Neurotherapeutics. 2010 Jan;7(1):22-30
20129494
Neuropsychopharmacology. 2006 Dec;31(12):2619-26
16823390
Front Neuroendocrinol. 2009 Jan;30(1):30-45
19017533